Pulmonary Arterial Hypertension (PAH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Pulmonary arterial hypertension (PAH) is a progressive and chronic condition marked by antiproliferative changes in the pulmonary arterioles, resulting in endothelial and smooth muscle proliferation and dysfunction, inflammation, and the formation of blood clots. PAH is primarily caused by remodeling pulmonary arteries, narrowing and obstructing the smallest arteries. This increased resistance in the pulmonary circulation results in elevated pressure within the right ventricle. Specific gene mutations, including BMPR2 (2q33), ACVRL1 (12q13), Endoglin (9q34), CAV1 (7q31), KCNK3 (2p23), Smad9 (13q12), and TBX4 (17q21), have been associated with heritable PAH. Most cases of PAH typically develop in adults, with occasional occurrences in children. Women are twice as likely as men to be affected by this condition. Initial symptoms include shortness of breath, fainting, chest discomfort, palpitations, and swelling in the lower extremities. Clinical signs include a prominent and palpable second heart sound, a pulmonary ejection click, and murmurs related to pulmonary and tricuspid regurgitation—approximately 70% of patients present with severe heart failure. Less frequently, symptoms such as abdominal swelling, clubbing of the fingers, and Raynaud's phenomenon (predominantly in females) may also manifest. Hemoptysis has been reported but is relatively rare. Treatment strategies encompass general measures, such as aggressive management of respiratory tract infections, annual influenza vaccinations, family planning, and medical therapies like oxygen supplementation, anticoagulation, diuretics, and digoxin. Calcium channel blockers are appropriate for patients with acute vasodilator response to nitric oxide during right heart catheterization. Additional therapeutic options include endothelin receptor agonists like ambrisentan, prostanoids like epoprostenol, and phosphodiesterase inhibitors like sildenafil. Lung transplantation remains the last resort for patients who do not respond to other treatment modalities. The prognosis varies depending on the specific form of PAH, but it is generally grim, with a mean survival rate of less than three years following diagnosis. However, early intervention with appropriate therapies can improve survival rates.

 

Thelansis’s “Pulmonary Arterial Hypertension (PAH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pulmonary Arterial Hypertension (PAH) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Pulmonary Arterial Hypertension (PAH) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Pulmonary Arterial Hypertension (PAH) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Pulmonary Arterial Hypertension (PAH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) market outlook, Pulmonary Arterial Hypertension (PAH) competitive landscape, Pulmonary Arterial Hypertension (PAH) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)